Billable / Specific Code
ICD-10-CM G37.81 is the diagnosis code for Myelin oligodendrocyte glycoprotein antibody disease. This code falls under the section "Demyelinating diseases of the central nervous system" within Chapter 6 — Diseases of the nervous system (G00-G99). It is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Medical coders and healthcare providers use this code to document and classify diagnoses in electronic health records, insurance claims, and clinical databases.
Understanding where G37.81 sits in the ICD-10-CM classification helps ensure proper coding:
Yes, G37.81 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
G37.81 is the ICD-10-CM diagnosis code for "Myelin oligodendrocyte glycoprotein antibody disease". It is used by healthcare providers to classify and document this condition in medical records and insurance claims.
The parent code of G37.81 is G37.8 ("Other specified demyelinating diseases of central nervous system"). G37.81 provides a more specific classification within this category.
G37.81 is located in Section G35-G37 — "Demyelinating diseases of the central nervous system" within Chapter 6 of the ICD-10-CM Tabular List.
Use G37.81 when the patients documented diagnosis matches "Myelin oligodendrocyte glycoprotein antibody disease" and the clinical documentation supports this level of specificity. Always verify with the latest ICD-10-CM guidelines and payer requirements.
The ICD-10-CM code for Myelin oligodendrocyte glycoprotein antibody disease is G37.81.
Yes, G37.81 can be used as a primary diagnosis code since it is billable and specific.
G37.81 is in Chapter 6 of the ICD-10-CM Tabular List.
Yes, G37.81 is a valid ICD-10-CM code for the 2026 fiscal year, subject to official CMS updates.